Journal of Clinical Oncology
Articles in this Issue
Determining individual preferences for gynecomastia avoidance among men with prostate cancer: A qualitative study.
TPS407 Background: Biochemical recurrence (BCR) affects 20–50% of men within 10 years of primary therapy for prostate canc...
Are long-term remissions possible with hormonal therapy only? Post hoc analysis of EMBARK examining sustained prostate-specific antigen (PSA) <0.2 ng/mL despite testosterone (T) recovery after treatment (tx) suspension.
189 Background: The phase 3 EMBARK trial (NCT02319837) assessed enzalutamide plus leuprolide (enza combo), leuprolide alon...
Clinical outcomes and tolerability of ipilimumab/nivolumab in older (≥70 years) versus younger patients with metastatic clear cell RCC: A multi-institutional analysis of 514 patients.
444 Background: Ipilimumab plus nivolumab (I/N) is a standard first-line treatment for metastatic clear cell renal cell ca...
Neoadjuvant treatment with disitamab vedotin plus perioperative toripalimab in patients with HER2-expressing muscle-invasive bladder cancer (MIBC) in the phase II RC48-C017 trial: Updated results.
766 Background: Disitamab vedotin (DV, a HER2-targeted antibody-drug conjugate with monomethyl auristatin E as the payload...
Deferred cytoreductive nephrectomy in patients with advanced RCC treated with first-line nivolumab plus ipilimumab: A propensity score-matched analysis from the RENOIR study (KCSG GU22-13).
439 Background: Despite limited supporting evidence, deferred cytoreductive nephrectomy (dCN) has been regarded a useful t...
Extracellular vesicles (EVs) and circulating tumor DNA (ctDNA) as potential biomarkers of response to <sup>177</sup> Lu-PSMA-617.
214 Background: 177 Lu-PSMA-617 (LuPSMA) has revolutionized care for patients (pts) with metastatic ca...
Peripheral blood correlates of outcomes with adjuvant tremelimumab plus durvalumab for patients with renal cell carcinoma at high or intermediate risk of relapse: Initial results from the TransRAMPART study.
527 Background: Despite optimal surgery, approximately 1/3 of patients with renal cell carcinoma (RCC) develop incurable r...
Transcriptomic deep learning approach for predicting chemotherapy response to cisplatin and gemcitabine in urothelial carcinoma.
786 Background: Chemotherapy with cisplatin and gemcitabine remains the cornerstone of treatment for advanced urothelial c...
Fostering inclusive language for genitourinary cancer research: A multi-stakeholder co-creation effort.
869 Background: Thoughtful patient inclusion, involving people of all literacy levels and experiences, is essential in can...
Clinical and genomic correlates of brain metastases in small cell carcinoma of the bladder.
807 Background: Small cell carcinoma of the bladder (SCCB) is a rare but aggressive subtype with a ~10% cumulative inciden...
EXTRA-PC: A phase II trial of masofaniten (EPI-7386) and enzalutamide with androgen deprivation therapy (ADT) for patients with metastatic hormone-sensitive prostate cancer (mHSPC).
148 Background: Masofaniten is a next-generation aniten which showed promising activity and safety in patients with metast...
KEYMAKER-U04 substudy 04B: First-line (1L) enfortumab vedotin (EV) plus pembrolizumab (pembro)-based immune checkpoint inhibitor (ICI) combinations for advanced urothelial cancer (UC).
634 Background: EV + pembro is the preferred standard 1L therapy for patients with locally advanced or metastatic UC (la/m...
ProTACT: A first-in-human, phase 1 study evaluating the safety, tolerability, and anti-tumor activity of [ <sup>225</sup> Ac]Ac-FL-020, an anti-PSMA radioconjugate in patients with mCRPC.
164 Background: [ 225 Ac]Ac-FL-020 is a next-generation, prostate-specific membran...
A phase 1b/2 study of FOR46 in combination with enzalutamide (enza) in patients with metastatic castration resistant prostate cancer (mCRPC).
149 Background: FOR46 is a monomethyl auristatin E antibody-drug conjugate targeting a tumor-specific epitope of CD46 that...
Pilot phase I trial of an implantable microdevice for in vivo evaluation of drug response in renal cell carcinoma.
540 Background: Optimal treatment selection in renal cell carcinoma (RCC) remains challenging, but individual biomarkers b...
Multi-hit <i>PIK3CA</i> mutations in clinically advanced (CA) penile squamous cell carcinoma (penSCC): A genomic landscape study.
10 Background: Recent evidence confirms that tumors, such as advanced hormone receptor-positive breast cancer, can be high...
A phase 1/2, first-in-human study of AVZO-103, a bispecific Nectin4/Trop2 antibody-drug conjugate (ADC), as monotherapy and in combination therapy in patients with locally advanced or metastatic urothelial cancer (UC) or other solid tumors.
TPS908 Background: Nectin4 and TROP2 are transmembrane proteins frequently overexpressed in UC and other solid tumors, but...
Drug-releasing intravesical floating technology (DRIFT) for administration of sequential gemcitabine and docetaxel in non-muscle-invasive bladder cancer.
784 Background: Sequential intravesical gemcitabine and docetaxel (Gem/Doce) is a well-tolerated, efficacious option in a...
Treatment of recurrent non-muscle invasive bladder cancer with UGN-301 (zalifrelimab) alone and in combination: A phase 1 dose escalation study.
752 Background: High-grade (HG) and intermediate-risk (IR) non-muscle invasive bladder cancer (NMIBC) often recurs/progres...
Artificial intelligence in the diagnosis and prognosis of upper tract urothelial carcinoma: A comprehensive review of current evidence, methodological standards, and future directions.
870 Background: Upper tract urothelial carcinoma (UTUC) is a rare malignancy (5–10% of urothelial cancers) with challengin...
Immune checkpoint inhibitor combinations in sarcomatoid metastatic clear cell renal cell carcinoma: A systematic review and meta-analysis.
483 Background: Sarcomatoid dedifferentiation (sRCC) in metastatic clear-cell renal cell carcinoma (mccRCC) confers aggres...
Outcomes with subsequent therapies post-enfortumab vedotin/pembrolizumab (EVP) in patients (pts) with advanced urothelial carcinoma (aUC): Analysis of the UNITE study.
705 Background: EVP is now the preferred first line (1L) treatment (tx) for aUC. However, outcomes with subsequent therapi...
Survivorship outcomes of stage I testis cancer management.
605 Background: Patients with stage I testicular cancer (TCa) have excellent survival, and surveillance after orchiectomy...
Impact of serum LDH on clinical outcomes in patients with good-risk metastatic non-seminomatous germ cell-cell tumors (NSGCT).
588 Background: In pts with NSGCT, serum AFP, hCG and LDH play an important role in staging, risk stratification and choic...
Urinary tumor DNA (utDNA) and circulating tumor DNA (ctDNA) in patients (pts) with muscle-invasive bladder cancer (MIBC) who received perioperative durvalumab (D) in NIAGARA.
636 Background: In NIAGARA (NCT03732677), addition of perioperative D to neoadjuvant chemotherapy (NAC) and radical cystec...